Lymphocyte proliferation specific for recall, CMV and HIV antigens in miniaturized and automated format

Area of Science:

• Immunology
• Cellular immunology
• T-cell assays

Background:

• Lymphoproliferation assay (LPA) is crucial for assessing T-cell responses.
• Standard LPA requires substantial peripheral blood mononuclear cells (PBMC), limiting high-throughput antigen screening.
• Insufficient PBMC numbers hinder epitope mapping and pathogen-derived antigenic panel evaluation.

Purpose of the Study:

• To develop a miniaturized and automated LPA for reduced PBMC consumption.
• To validate the reliability and sensitivity of the miniaturized LPA.
• To enable high-throughput screening of numerous antigens with limited cell numbers.

Main Methods:

• Developed a miniaturized LPA protocol for 384- and 1536-well plates.
• Reduced PBMC input to one-fourth to one-twentieth of standard assay requirements.
• Validated using recall antigens and CMV/HIV protein and peptide antigens, alongside HIV-specific T-cell lines.

Main Results:

• Demonstrated a reliable and robust miniaturized LPA procedure.
• Achieved sensitivity overlapping with standard LPA, detecting as few as 3 specific T-cells/well.
• Confirmed the method's efficacy with diverse recall and pathogen-derived antigens.

Conclusions:

• The miniaturized LPA significantly reduces PBMC requirements while maintaining assay sensitivity and reliability.
• This automated, high-throughput method is suitable for epitope mapping and screening antigenic panels.
• The established procedure aligns with the ongoing effort to miniaturize assays for specific T-cell immunity.